Christopher Melani

Also affiliated with National Cancer Institute, Center for Cancer Research

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma”.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Journal of Clinical Oncology(2020)10.1200/jco.20.00303

N/A

5.0DataRank · unranked

152 citations

Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel +19 more

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

New England Journal of Medicine(2024)10.1056/nejmoa2401532

N/A

1.5DataRank · unranked

68 citations

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Da Wei Huang, George W. Wright +31 more

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Blood Advances(2022)10.1182/bloodadvances.2021006397

N/A

1.3DataRank · unranked

44 citations

Christopher Melani, Kieron Dunleavy, Stefania Pittaluga, Nakhle S. Saba, Liza Lindenberg +11 more

Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL

Blood Advances(2021)10.1182/bloodadvances.2020003679

N/A

0.828DataRank · unranked

22 citations

Christopher Melani, Stefania Pittaluga, Rahul Lakhotia, Andrea N. Lucas, Allison P. Jacob +5 more

Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial

The Lancet Haematology(2023)10.1016/s2352-3026(23)00029-7

N/A

0.493DataRank · unranked

14 citations

Kennichi Dowdell, Stefania Pittaluga, Kieron Dunleavy, Mark Roschewski, Joo Y. Song +11 more

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology(2025)10.1111/bjh.20219

N/A

0.241DataRank · unranked

4 citations

Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan Muppidi +7 more

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Blood Neoplasia(2024)10.1016/j.bneo.2024.100054

N/A

0.165DataRank · unranked

2 citations

Sigrid Dubois, Miloš D. Miljković, Samuel Y. Ng, Bonita R. Bryant, Rahul Lakhotia +8 more

Venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) and treatment‐naïve (TN) mantle cell lymphoma (MCL)

Hematological Oncology(2023)10.1002/hon.3164_437

N/A

0.104DataRank · unranked

1 citations

Rahul Lakhotia, Stefania Pittaluga, J. D. Phelan, Y. Yang, Theresa Davies‐Hill +17 more

Enitociclib ( VIP152 ), venetoclax and prednisone in relapsed or refractory aggressive non‐Hodgkin lymphoma

British Journal of Haematology(2025)10.1111/bjh.70234

N/A

0DataRank · unranked

1 citations

Rahul Lakhotia, Stefania Pittaluga, Svetlana Pack, Anna Marie Juanitez, Ahmed Hamdy +8 more

Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma

Blood Cancer Discovery(2020)10.1158/2643-3230.bcd-20-0009

N/A

0DataRank · unranked

48 citations

Alina Nicolae, George W. Wright, Christopher Melani, Mark Roschewski, Seth M. Steinberg +5 more

Malignancy in STAT3 Deficient Hyper IgE Syndrome

Journal of Clinical Immunology(2022)10.1007/s10875-021-01197-y

N/A

0DataRank · unranked

8 citations

Christopher Melani, Mark Roschewski, Wyndham H. Wilson, Stefania Pittaluga, Haig Tcheurekdjian +4 more

Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Advances(2023)10.1182/bloodadvances.2023010223

N/A

0DataRank · unranked

0 citations

Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani +10 more

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2413372121

N/A

0DataRank · unranked

8 citations

Frances A. Tosto, Xiaohu Zhang, Christopher Melani, Mark Roschewski, Erin Beck +13 more

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Maryland Shared Open Access Repository (USMAI Consortium)(2024)10.13016/m2trio-fqf2

N/A

0DataRank · unranked

0 citations

Sigrid Dubois, Miloš Miljkovi?, Samuel Y. Ng, Bonita R Bryant, Rahul Lakhotia +8 more

An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors

ACS Pharmacology & Translational Science(2025)10.1021/acsptsci.5c00412

N/A

0DataRank · unranked

2 citations

Xiaohu Zhang, Patricia Alfonso, Patrick J. Morris, Carleen Klumpp‐Thomas, Christopher Melani +12 more